Distribution of frequencies of wild-type and variant Gag sequences in viruses from <i>KIR2DL3+/HLA-C*03</i>:<i>04+</i> individuals compared to individuals not possessing the combined <i>KIR2DL3/HLA-C*03</i>:<i>04</i> genotype.

<p>(A) A valine (V) at amino acid position 303 of HIV-1 Gag was significantly (<i>p <</i> 0.001, Fisher`s exact test) overrepresented in <i>KIR2DL3+/HLA-C*03</i>:<i>04+</i> individuals (<i>n</i> = 33) compared to individuals not possessing this combined genotype (non-<i>KIR2DL3</i> and <i>HLA-C*03</i>:<i>04</i>, <i>n</i> = 348), 90% of whom had virus with the consensus sequence wild-type threonine (T) in that position (<i>n</i> = 312). Furthermore, an alanine (A) variant at position Gag₃₀₃ was present in five of the 33 individuals in the <i>KIR2DL3+/HLA-C*03</i>:<i>04+</i> group (15%). The percentage of individuals whose virus showed mixed residues at position Gag₃₀₃ was 0% in <i>KIR2DL3−/HLA-C*03</i>:<i>04</i>− individuals and 9% in <i>KIR2DL3+/HLA-C*03</i>:<i>04+</i> individuals. (B) An alanine (A) at position 340 of HIV-1 Gag was significantly (<i>p <</i> 0.001, Fisher’s exact test) overrepresented in <i>KIR2DL3+/HLA-C*03</i>:<i>04+</i> individuals (<i>n</i> = 35) compared to individuals not possessing this combined genotype (non-<i>KIR2DL3</i> and <i>HLA-C*03</i>:<i>04</i>, <i>n</i> = 353), 90% of whom had virus with the consensus sequence wild-type glycine (G) in that position (<i>n</i> = 316). Two patients in the <i>KIR2DL3−/HLA-C*03</i>:<i>04</i>− subset had neither the wild-type nor the G_Gag340A variant and are not shown in this graph. The percentage of individuals whose virus showed mixed residues at position Gag₃₄₀ was 1% in <i>KIR2DL3−/HLA-C*03</i>:<i>04</i>− individuals and 6% in <i>KIR2DL3+/HLA-C*03</i>:<i>04+</i> individuals. Conclusive KIR2DL3 typing was not available for two out of the 392 study participants; these two participants were excluded from further analysis.